lp-a.org

Epidemiology

Elevated Lp(a) predicts heart failure and major adverse cardiovascular events in peripheral artery disease (Circ J 2026)

Original title: Elevated Lipoprotein(a) Is Associated With Heart Failure in Patients With Peripheral Artery Disease

Circ J · · 4

Hoshina R, Akahori H, Tanaka H, Yoshihara N, Miki K, Kawai K, Ishihara M

This retrospective cohort of 138 patients with peripheral artery disease undergoing endovascular therapy classified participants by Lp(a) level (≥30 vs. <30 mg/dL). Elevated Lp(a) was associated with a higher incidence of major adverse cardiovascular events (31.1% vs. 9.6%; P=0.002), predominantly driven by heart failure. Lp(a) independently predicted major adverse cardiovascular events (HR 4.23) and heart failure (HR 5.12), but did not predict cardiovascular death, myocardial infarction or stroke. The results highlight a heart failure-specific risk signal, warranting validation in larger prospective cohorts.

Read the paper (DOI)PubMed

Original abstract

Background: The prognostic value of lipoprotein(a) [Lp(a)] in peripheral artery disease (PAD) remains uncertain.

Methods And Results: We retrospectively studied 138 patients with intermittent claudication undergoing endovascular therapy. Patients were classified by Lp(a) level (≥30 vs. <30 mg/dL). The primary endpoint was major adverse cardiovascular events (MACE). Elevated Lp(a) was associated with a higher incidence of MACE (31.1% vs. 9.6%; P=0.002), predominantly driven by heart failure. It independently predicted MACE (HR 4.23) and heart failure (HR 5.12), but not cardiovascular death, myocardial infarction or stroke.

Conclusions: Elevated Lp(a) was associated with heart failure-driven MACE after endovascular therapy in patients with PAD.

epidemiologyheart failurerisk prediction

Summary written by lp-a.org from the published abstract; figures as published. Page updated 14 November 2026. Methods.